Effectiveness of Acceptance and Commitment Therapy on the Life Expectancy, Resilience and Death Anxiety in Women with Cancer

Introduction: An annual record of 90,000 new cases of cancer in Iran and a mortality rate of 55,000 affected cases is indicative of alarming outbreak of cancer in the country to the extent that an average of 100 people die each day due to this disease. The purpose of the present research is to evaluate the effectiveness of acceptance and commitment therapy (ACT) on the life expectancy, resilience and death anxiety in women with cancer.Methods: The present research is a semi-experimental research with pretest-posttest control group design. The research population consisted of all women with cancer who referred to the Cancer Institute of Imam Khomeini Hospital in Tehran in 2017. Thirty women who met the inclusion criteria were randomly divided into two groups: experimental and control. Life expectancy, resilience and death anxiety scales were used and multivariate covariance analysis was applied for data analysis.Results: The results showed that life expectancy increased in the experimental group in compare with the control group (p<0.05) and the death anxiety of the experimental group decreased in compare to the control group (p<0.05) after acceptance and commitment training.Conclusion: Acceptance and commitment therapy is effective in increasing the life expectancy and resilience and also in decreasing death Anxiety in women patient with cancer. These findings can be used in designing of psychological treatment interventions in the field of cancer.Declaration of Interest: Non

Investigation of PsychometricProperties of Psychosomatic Complaints Scale among Individuals with Somatic Symptom Disorder

Background and Aim:Given the prevalence of somatic symptoms disorder among Iranians, the aim of this research is to evaluate and verify the psychometric characteristics of Takata and Sakata psychosomatic complaints scale among psychosomatic patients. Materials and Methods:In this study 360 people who referred to the psychosomatics department of Taleghani Hospital in Tehran in 2022, as well as the patients referred by the physicians, psychiatrists and psychologists of medical centers were selected through convenience sampling method. Internal consistency method (Cronbach's alpha) was used to determine the reliability of the questionnaire. Also, exploratory factor analysis and confirmatory factor analysis were used to determine the factor structure. To ensure convergent validity, Goldberg general health scale (GHQ-28) was used and SPSS and Lisrel software were applied for analyzing data. Results:The results of the Cronbach's alpha indicated the appropriate internal consistency of the whole questionnaire and its components. Cronbach's alpha for the whole questionnaire was 0.957. In the exploratory factor analysis, a "hyper stimulation" factor was extracted. According to confirmatory factor analysis, the goodness of fit indicators of proposed model were confirmed (Chi-Square/df: 1.297, RMSEA: 0.029, SRMR: 0.031, CFI: 0.976, IFI: 0.976) and all paths were significant. Regarding the convergent validity, somatic symptoms component, anxiety, dysfunction in social action and function, and depression have a direct and significant relationship with psychosomatic problems. Conclusion:The Persianversion of the takata and sakata psychosomatic complaints scale, is a reliable and valid tool for assessing of the severity of psychosomatic symptoms in Iranian psychosomatic patients

Mesostigmata diversity by manure type. A reference study and new datasets from southwestern Iran.

Manure-inhabiting Mesostigmata mites are important biological control agents of pest flies. However, the biodiversity of this mite community is mainly known from Europe or America and, especially, from cattle manure. This study examined the diversity and abundance of Mesostigmata mites associated with different types of manure in an (intensive) agricultural region of the middle East, Ahvaz and its suburbs, southwest Iran. Mite samples were extracted from manure of cattle, buffalo, sheep, horse, poultry and quail in 30 livestock and poultry farms. In total, 40 species belonging to 24 genera and 16 families were identified. The most diverse families were Laelapidae with eight species, Macrochelidae with seven and Parasitidae with six. Macrocheles muscaedomesticae and Uroobovella marginata were the most widespread species, recorded in 28 and 27 out of 30 collecting sites, respectively. Two species, M. sumbaensis and U. marginata, were found in all studied manures. Simpson’s diversity index recorded the highest diversity in buffalo and sheep manure. Real and theoretical species richness (rarefaction curves) were congruent in number of individuals. The presence of seven species of Macrochelidae in the manure confirms that these are important predators of the house fly for the region of Ahvaz and its suburbs. Members of the Parasitidae were highly prevalent; with one species known as a specialized predator of house fly eggs. This work aims to encourage further studies on the biology and the predatory traits of these Mesostigmata, to continue assessing the feasibility of these mites as effective biological control agents of filth flies in different types of manure and from different corners of the world

Effect of the CXCR4 antagonist plerixafor on endogenous neutrophil dynamics in the bone marrow, lung and spleen

Treatment with the CXCR4 antagonist, plerixafor (AMD3100), has been proposed for clinical use in patients with WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome and in pulmonary fibrosis. However, there is controversy with respect to the impact of plerixafor on neutrophil dynamics in the lung, which may affect its safety profile. In this study we investigated the kinetics of endogenous neutrophils by direct imaging, using confocal intravital microscopy in mouse bone marrow, spleen and lungs. Neutrophils are observed increasing their velocity and exiting the bone marrow following plerixafor administration, with a concomitant increase in neutrophil numbers in the blood and spleen, while the marginated pool of neutrophils in the lung microvasculature remained unchanged in terms of numbers and cell velocity. Use of autologous radiolabeled neutrophils and SPECT/CT imaging in healthy volunteers showed that plerixafor did not affect GM-CSF-primed neutrophil entrapment or release in the lungs. Taken together these data suggest that plerixafor causes neutrophil mobilization from the bone marrow but does not impact on lung marginated neutrophil dynamics and thus is unlikely to compromise respiratory host defense both in humans and mice.This work was funded by a grant provided to JP by the Lung Foundation Netherlands (5.2.14.058JO), the NIHR Cambridge Biomedical Research Centre and NIHR Imperial Biomedical Research Centre. ERC and CS’ laboratories receive grant support from the Medical Research Council, Wellcome Trust, NIHR, GlaxoSmithKline, MedImmune Ltd., and Bristol-Myers Squibb. CLC is supported by Bloodwise (12033), CRUK (C36195/A1183) and European Research Council (ERC) (337066). CP is supported by Bloodwise (12033). The Facility for Imaging by Light Microscopy (FILM) at Imperial College London is part-supported by funding from the Wellcome Trust (grant 104931/Z/14/Z) and BBSRC (grant BB/L015129/1). KDF is supported by funding from the Wellcome Trust (201356/Z/16/Z). LMC is supported by core funding from Cancer Research UK (A23983 and A17196)

The MKK7-MPK6 MAP Kinase Module Is a Regulator of Meristem Quiescence or Active Growth in Arabidopsis

Plant growth flexibly adapts to environmental conditions. Growth initiation itself may be conditional to a suitable environment, while the most common response of plants to adverse conditions is growth inhibition. Most of our understanding about environmental growth inhibition comes from studies on various plant hormones, while less is known about the signaling mechanisms involved. The mitogen-activated protein kinase (MAPK) cascades are central signal transduction pathways in all eukaryotes and their roles in plant stress responses is well-established, while increasing evidence points to their involvement in hormonal and developmental processes. Here we show that the MKK7-MPK6 module is a suppressor of meristem activity using genetic approaches. Shoot apical meristem activation during light-induced de-etiolation is accelerated in mpk6 and mkk7 seedlings, whereas constitutive or induced overexpression of MKK7 results in meristem defects or collapse, both in the shoot and the root apical meristems. These results underscore the role of stress-activated MAPK signaling in regulating growth responses at the whole plant level, which may be an important regulatory mechanism underlying the environmental plasticity of plant development

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Bisexual and oedipal reproduction of Macrocheles muscaedomesticae (Acari, Macrochelidae) feeding on Musca domestica (Diptera, Muscidae) eggs

Farahi, Sara, Shishehbor, Parviz, Nemati, Alireza (2018): Bisexual and oedipal reproduction of Macrocheles muscaedomesticae (Acari, Macrochelidae) feeding on Musca domestica (Diptera, Muscidae) eggs. Acarologia 58 (2): 430-441, DOI: 10.24349/acarologia/20184251, URL: http://dx.doi.org/10.24349/acarologia/2018425